0 193

Cited 8 times in

Pharmacokinetic Interaction Between Amlodipine and Lobeglitazone, a Novel Peroxisome Proliferator–activated Receptor-γ Agonist, in Healthy Subjects

DC FieldValueLanguage
dc.contributor.author박민수-
dc.contributor.author김춘옥-
dc.date.accessioned2016-02-04T12:04:10Z-
dc.date.available2016-02-04T12:04:10Z-
dc.date.issued2015-
dc.identifier.issn0149-2918-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/141822-
dc.description.abstractPurpose : Lobeglitazone, a peroxisome proliferator–activated receptor-γ agonist, was developed for the treatment of diabetes mellitus. Because the prevalence of hypertension is high among patients with diabetes mellitus, lobeglitazone is likely to be used with the antihypertensive drug amlodipine. We evaluated the pharmacokinetic interactions between lobeglitazone and amlodipine in healthy male Korean subjects. Methods : The study used a randomized, open-label, multiple-dose, 3-treatment, 3-period, 6-sequence crossover design. A total of 24 healthy subjects were enrolled. Blood samples for pharmacokinetic analysis were collected according to a planned schedule after 0.5 mg of lobeglitazone and 10 mg of amlodipine were administered alone or concomitantly once per day for 10 days. Findings : A total of 24 healthy male subjects participated in the study (mean [SD] age, 26.6 [3.9] years; weight, 67.8 [5.7] kg; and height, 173.6 [6.4] cm). Three participants voluntarily withdrew after the second period, and 1 participant dropped out because of increased creatinine kinase levels caused by strenuous exercise before the start of the third period. Thus, 21 participants completed the study schedule to compare the pharmacokinetic parameters of lobeglitazone, and 22 participants completed the study of amlodipine. The geometric mean ratio (with 90% CIs) of Cmax,ss and AUCτ,ss for lobeglitazone administered concomitantly with amlodipine versus lobeglitazone administered alone was 1.01 (0.93–1.09) and 1.06 (0.92–1.23), respectively. The geometric mean ratio (with 90% CIs) of Cmax,ss and AUCτ,ss for amlodipine administered concomitantly with lobeglitazone versus amlodipine administered alone was 0.98 (0.94–1.02) and 1.00 (0.96–1.05). No serious drug-induced adverse events were reported in the study, and no clinically significant changes in vital signs, physical examination results, clinical laboratory results, or ECGs were noted.-
dc.description.statementOfResponsibilityopen-
dc.format.extent1999~2006-
dc.relation.isPartOfCLINICAL THERAPEUTICS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAmlodipine/administration & dosage-
dc.subject.MESHAmlodipine/blood-
dc.subject.MESHAmlodipine/pharmacokinetics*-
dc.subject.MESHAntihypertensive Agents/administration & dosage-
dc.subject.MESHAntihypertensive Agents/blood-
dc.subject.MESHAntihypertensive Agents/pharmacokinetics*-
dc.subject.MESHArea Under Curve-
dc.subject.MESHAsian Continental Ancestry Group-
dc.subject.MESHCross-Over Studies-
dc.subject.MESHDrug Interactions-
dc.subject.MESHHealthy Volunteers-
dc.subject.MESHHumans-
dc.subject.MESHHypoglycemic Agents/administration & dosage-
dc.subject.MESHHypoglycemic Agents/blood-
dc.subject.MESHHypoglycemic Agents/pharmacokinetics*-
dc.subject.MESHMale-
dc.subject.MESHPPAR gamma/agonists-
dc.subject.MESHPyrimidines/administration & dosage-
dc.subject.MESHPyrimidines/blood-
dc.subject.MESHPyrimidines/pharmacokinetics*-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHThiazolidinediones/administration & dosage-
dc.subject.MESHThiazolidinediones/blood-
dc.subject.MESHThiazolidinediones/pharmacokinetics*-
dc.subject.MESHYoung Adult-
dc.titlePharmacokinetic Interaction Between Amlodipine and Lobeglitazone, a Novel Peroxisome Proliferator–activated Receptor-γ Agonist, in Healthy Subjects-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Pediatrics (소아과학)-
dc.contributor.googleauthorKim Choon OK-
dc.contributor.googleauthorSil Oh Eun-
dc.contributor.googleauthorPark Min Soo-
dc.contributor.googleauthorKim Chin-
dc.identifier.doi10.1016/j.clinthera.2015.06.009-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01468-
dc.contributor.localIdA04735-
dc.relation.journalcodeJ00614-
dc.identifier.eissn1879-114X-
dc.identifier.pmid26163202-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0149291815008723-
dc.subject.keywordamlodipine-
dc.subject.keywordinteraction-
dc.subject.keywordlobeglitazone-
dc.subject.keywordpharmacokinetics-
dc.contributor.alternativeNamePark, Min Soo-
dc.contributor.affiliatedAuthorPark, Min Soo-
dc.rights.accessRightsnot free-
dc.citation.volume37-
dc.citation.number9-
dc.citation.startPage1999-
dc.citation.endPage2006-
dc.identifier.bibliographicCitationCLINICAL THERAPEUTICS, Vol.37(9) : 1999-2006, 2015-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아청소년과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.